Get startedLog in
    Picture of Sanofi SA logo

    SAN — Sanofi SA News Story

    0.000.00%
    fr flag iconLast trade - 00:00
    HealthcareBalancedLarge CapSuper Stock
    All News

    Brief: Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma

    Picture of Sanofi SA logoSanofi SA
    19/06/2026 11:33
    BRIEF-Sanofi’s Sarclisa Subcutaneous Formulation Approved In Japan For Patients With Multiple Myeloma
    June 19 (Reuters) - Sanofi SA SASY.PA:
    • PRESS RELEASE: SANOFI’S SARCLISA SUBCUTANEOUS FORMULATION APPROVED IN JAPAN FOR PATIENTS WITH MULTIPLE MYELOMA
    • APPROVAL BASED ON IRAKLIA PHASE 3 STUDY SHOWING NON-INFERIOR EFFICACY TO IV
    • CIRCLIQ ON-BODY INJECTOR FOR SARCLISA SC UNDER REVIEW IN JAPAN
    • SARCLISA SC VIA OBI PLUS PD SHOWS 71.1% ORR IN R/R MM
    Source text: nGNXbmwK8R
    Further company coverage: SASY.PA

     (Gdansk Newsroom)
     ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))

    Recent news on Sanofi SA

    See all news